Title:
PHARMACEUTICAL COMPOSITION AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/035223
Kind Code:
A1
Abstract:
Provided in the present invention are a pharmaceutical composition containing a therapeutically effective amount of Furmonertinib or a pharmaceutically acceptable salt thereof and optionally a pharmaceutically acceptable carrier, and the use of the pharmaceutical composition in the preparation of a drug for treating and/or preventing a disease mediated by exon 20 insertion mutation of EGFR. The pharmaceutical composition of the present invention exhibits an excellent therapeutic effect for a disease (eg, non-small cell lung cancer (NSCLC)) mediated by exon 20 insertion mutation of EGFR, and has mild side effects and excellent safety.
Inventors:
LUO HUIBING (CN)
LI QING (CN)
LI QING (CN)
Application Number:
PCT/CN2021/117692
Publication Date:
March 16, 2023
Filing Date:
September 10, 2021
Export Citation:
Assignee:
SHANGHAI ALLIST PHARMACEUTICALS CO LTD (CN)
International Classes:
A61K31/506; A61P35/00; C07C303/32; C07C309/04; C07D401/14; C07D471/04
Foreign References:
| CN107163026A | 2017-09-15 | |||
| CN107163027A | 2017-09-15 | |||
| CN105315259A | 2016-02-10 |
Other References:
SHANGHAI AILISI PHARMACEUTICAL TECHNOLOGY CO., LTD.: "Phase IB clinical study of fometinib mesylate in the treatment of EGFR exon 20 insertion mutations", CHINADRUGTRIALS, vol. CTR20201697, pages 1, XP009544560, Retrieved from the Internet
Attorney, Agent or Firm:
CHINA PATENT AGENT (H.K.) LTD. (CN)
Download PDF: